SWG 5: The primary purpose of the Curative Therapies SWG is to accelerate work toward a cure for HIV, by linking local investigators of curative therapies for HIV to the UW/FHCRC CFAR. SWG 5 will leverage a large NIH investment in the Seattle-led consortium defeat HIV, one of three Martin Delaney collaboratories focused on the cure of HIV. We intend to facilitate use of CFAR resources, including the clinical, basic science, and developmental cores, to leverage efficiencies of scale, develop novel research questions, and collectively pursue additional NIH and foundation-sponsored resources for the study of curative therapies for HIV. A secondary purpose is to link Seattle investigators with outside leaders in the field, to develop local expertise as well as enhance areas of local strength. These activities will add value to the UW/FHCRC CFAR, US CFARs generally, and defeat HIV, by establishing an international center of excellence in the study of curative therapies for HIV. SWG 6: The Substance Abuse (SA) SWG will consist of over 30 UW investigators working in four research emphasis areas: Sexual Behavior-Substance Abuse Nexus, Substance Abusing HIV Positive Individuals, Prevention of HIV among Substance Abusing Individuals, HIV/STI Epidemiology among Substance Abusers.
The aims of the SWG 6 are: 1) develop synergy and collaboration among local HIV substance abuse researchers, and 2) seek funding for identified collaborative opportunities and encourage early career and minority investigators to pursue substance abuse and HIV/STI related research. The success of the SA SWG will be determined by publication of manuscripts or acceptance of abstracts, and/or submissions for grant funding by SA SWG members and other CFAR investigators. SWG 7: Coverage gaps with efficacious interventions underscore the importance of improving knowledge translation and implementation to achieve scale.
The aim of the Implementation Science SWG is to improve the speed, efficiency and quality of translation of scientific evidence on HIV/STI prevention and care into effective, large scale health programs. SWG 7 will leverage local and international multidisciplinary expertise to develop innovative models for implementing and scaling-up efficacious HIV/STI interventions, and apply rigorous methods to develop a base of evidence to guide scale-up. Specific activities include bimonthly IS meetings to develop novel research methods for IS, foster interdisciplinary collaboration, and coordinate responses to funding opportunities;annual IS symposia;fostering collaboration among CFAR cores and extra-CFAR institutions;and IS education, training and mentoring internationally and at the UW.

Public Health Relevance

Our 3 proposed SWGs propose to promote collaborations and accelerate the pace of research in three areas: Curative Therapies for HIV, bringing together scientists with many different areas of expertise to help them work toward a cure for HIV;Substance Abuse and HIV/STI, addressing the challenges presented by the intersection of substance abuse and HIV infection;and Implementation Science, providing critical resources to improve the quality of research and maximize the impact of HIV interventions worldwide.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027757-27
Application #
8683044
Study Section
Special Emphasis Panel (ZAI1-UKS-A)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
27
Fiscal Year
2014
Total Cost
$128,731
Indirect Cost
$32,015
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Wagner, Anjuli D; O?Malley, Gabrielle; Firdawsi, Olivia et al. (2018) Brief Report: Disclosure, Consent, Opportunity Costs, and Inaccurate Risk Assessment Deter Pediatric HIV Testing: A Mixed-Methods Study. J Acquir Immune Defic Syndr 77:393-399
Golovaty, Ilya; Sharma, Monisha; Van Heerden, Alastair et al. (2018) Cost of Integrating Noncommunicable Disease Screening Into Home-Based HIV Testing and Counseling in South Africa. J Acquir Immune Defic Syndr 78:522-526
LaCourse, Sylvia M; Cranmer, Lisa M; Njuguna, Irene N et al. (2018) Urine Tuberculosis Lipoarabinomannan Predicts Mortality in Hospitalized Human Immunodeficiency Virus-Infected Children. Clin Infect Dis 66:1798-1801
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Patel, Rena C; Bukusi, Elizabeth A; Baeten, Jared M (2018) Current and future contraceptive options for women living with HIV. Expert Opin Pharmacother 19:1-12
Ross, Jennifer M; Ying, Roger; Celum, Connie L et al. (2018) Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. Epidemics 23:34-41
Wagner, Anjuli D; Shah, Seema K; Njuguna, Irene N et al. (2018) Financial Incentives to Motivate Pediatric HIV Testing-Assessing the Potential for Coercion, Inducement, and Voluntariness. J Acquir Immune Defic Syndr 78:e15-e18
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537

Showing the most recent 10 out of 1275 publications